Your browser doesn't support javascript.
loading
Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection.
Nadkami, Girish; Paranjpe, Ishan; Jayaraman, Pushkala; Su, Chen-Yang; Zhou, Sirui; Chen, Steven; Valle, Diane Del; Thompson, Ryan; Kenigsberg, Ephraim; Zhao, Shan; Jaladanki, Suraj; Chaudhary, Kumardeep; Ascolillo, Steven; Vaid, Akhil; Gonzalez-Kozlova, Edgar; Kumar, Arvind; Paranjpe, Manish; O'Hagan, Ross; Kamat, Samir; Gulamali, Faris; Kauffman, Justin; Xie, Hui; Harris, Joceyln; Patel, Manishkumar; Argueta, Kimberly; Batchelor, Craig; Nie, Kai; Dellepiane, Sergio; Scott, Leisha; Levin, Matthew; He, John; Suárez-Fariñas, Mayte; Coca, Steven; Chan, Lili; Azeloglu, Evren; Schadt, Eric; Beckmann, Noam; Gnjatic, Sacha; Merad, Miriam; Kim-Schulze, Seunghee; Richards, J Brent; Glicksberg, Benjamin; Charney, Alexander.
Afiliação
  • Nadkami G; Icahn School of Medicine at Mount Sinai.
  • Paranjpe I; Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY USA.
  • Jayaraman P; Icahn School of Medicine at Mount Sinai.
  • Su CY; McGill University.
  • Zhou S; Lady Davis Institute.
  • Chen S; Icahn School of Medicine at Mount Sinai.
  • Valle DD; Icahn School of Medicine at Mount Sinai.
  • Thompson R; Icahn School of Medicine at Mount Sinai.
  • Kenigsberg E; Icahn School of Medicine at Mount Sinai.
  • Zhao S; Icahn School of Medicine at Mount Sinai.
  • Jaladanki S; Icahn School of Medicine at Mount Sinai.
  • Chaudhary K; Icahn School of Medicine at Mount Sinai.
  • Ascolillo S; Icahn School of Medicine at Mount Sinai.
  • Vaid A; Icahn School of Medicine at Mount Sinai.
  • Gonzalez-Kozlova E; Mt Sinai School of Medicine.
  • Kumar A; Icahn School of Medicine at Mount Sinai.
  • Paranjpe M; Harvard Medical School.
  • O'Hagan R; Icahn School of Medicine at Mount Sinai.
  • Kamat S; Icahn School of Medicine at Mount Sinai.
  • Gulamali F; Icahn School of Medicine at Mount Sinai.
  • Kauffman J; Icahn School of Medicine at Mount Sinai.
  • Xie H; Icahn School of Medicine at Mount Sinai.
  • Harris J; Icahn School of Medicine at Mount Sinai.
  • Patel M; Icahn School of Medicine at Mount Sinai.
  • Argueta K; Icahn School of Medicine at Mount Sinai.
  • Batchelor C; Icahn School of Medicine at Mount Sinai.
  • Nie K; Icahn School of Medicine at Mount Sinai.
  • Dellepiane S; Icahn School of Medicine at Mount Sinai.
  • Scott L; Icahn School of Medicine at Mount Sinai.
  • Levin M; Icahn School of Medicine at Mount Sinai.
  • He J; Mount Sinai School of Medicine.
  • Suárez-Fariñas M; Icahn School of Medicine at Mount Sinai.
  • Chan L; Icahn School of Medicine at Mount Sinai.
  • Azeloglu E; Icahn School of Medicine at Mount Sinai.
  • Schadt E; Icahn School of Medicine at Mount Sinai.
  • Beckmann N; Icahn School of Medicine at Mount Sinai.
  • Gnjatic S; Icahn School of Medicine at Mount Sinai.
  • Merad M; Icahn School of Medicine at Mount Sinai.
  • Kim-Schulze S; Icahn School of Medicine at Mt. Sinai.
  • Richards JB; Lady Davis Institute for Medical Research, Jewish General Hospital.
  • Glicksberg B; Icahn School of Medicine at Mount Sinai.
  • Charney A; Icahn School of Medicine at Mount Sinai.
Res Sq ; 2023 Mar 16.
Article em En | MEDLINE | ID: mdl-36993735
ABSTRACT
Background Acute kidney injury (AKI) is a known complication of COVID-19 and is associated with an increased risk of in-hospital mortality. Unbiased proteomics using biological specimens can lead to improved risk stratification and discover pathophysiological mechanisms. Methods Using measurements of ~4000 plasma proteins in two cohorts of patients hospitalized with COVID-19, we discovered and validated markers of COVID-associated AKI (stage 2 or 3) and long-term kidney dysfunction. In the discovery cohort (N= 437), we identified 413 higher plasma abundances of protein targets and 40 lower plasma abundances of protein targets associated with COVID-AKI (adjusted p <0.05). Of these, 62 proteins were validated in an external cohort (p <0.05, N =261). Results We demonstrate that COVID-AKI is associated with increased markers of tubular injury ( NGAL ) and myocardial injury. Using estimated glomerular filtration (eGFR) measurements taken after discharge, we also find that 25 of the 62 AKI-associated proteins are significantly associated with decreased post-discharge eGFR (adjusted p <0.05). Proteins most strongly associated with decreased post-discharge eGFR included desmocollin-2 , trefoil factor 3 , transmembrane emp24 domain-containing protein 10 , and cystatin-C indicating tubular dysfunction and injury. Conclusions Using clinical and proteomic data, our results suggest that while both acute and long-term COVID-associated kidney dysfunction are associated with markers of tubular dysfunction, AKI is driven by a largely multifactorial process involving hemodynamic instability and myocardial damage.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Res Sq Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Res Sq Ano de publicação: 2023 Tipo de documento: Article